In conclusion, we report the first global untargeted proteomic analysis of leukemic cells in pediatric AML, leading to the validation of biological function between CBF and non-CBF AML subtypes and new insights into AML pathobiology and potential druggable targets. This evidence concerns the gene CEBPZ and acute myeloid leukemia.